Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Elan Ezickson | M | 60 |
Asylia Therapeutics, Inc.
 Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
| Jeno Gyuris | M | 64 |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
| Ronald DePinho | M | 69 |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | 5 anni |
| Karthik Radhakrishnan | M | 53 |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
| Alex M. Cranberg | M | - |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
| Rachel Humphrey | M | 62 |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
| Joseph Kekst | M | - |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Amit Rakhit | M | 54 |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | 1 anni |
| Richard Jones | M | - |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Asylia Therapeutics, Inc. is a private biotechnology company founded in 2019 by Richard Jones, Robert Z. Orlowski, and Ronald A. DePinho. The company is based in Houston, TX. Asylia Therapeutics is focused on developing novel immune modulating therapies for cancer and autoimmune diseases. The company's drug pipeline is capable of modulating antigen presentation to the immune system, which has produced anti-tumor responses across multiple cancer models. The company is supported by a $3 million grant from the Cancer Prevention & Research Institute of Texas. The CEO is Karthik Radhakrishnan. | - |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 9 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Robert Z. Orlowski
- Contatti personali
